BRIEF-Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted To Tividenofusp Alfa For The Treatment Of Hunter Syndrome (MPS II)

Reuters

08 Jan

BRIEF-Denali <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces U.S. FDA Breakthrough Therapy Designation Granted To Tividenofusp Alfa For The Treatment Of Hunter Syndrome (MPS II)

Jan 8 (Reuters) - Denali Therapeutics Inc DNLI.O:

DENALI THERAPEUTICS ANNOUNCES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION GRANTED TO TIVIDENOFUSP ALFA FOR THE TREATMENT OF HUNTER SYNDROME (MPS II)
DENALI THERAPEUTICS INC - EXPECTS TO SUBMIT BLA FOR TIVIDENOFUSP ALFA IN EARLY 2025

Source text: nGNX1hSTYb

Further company coverage: DNLI.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/news/2501727284"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501727284\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2501727284?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 21:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501727284","market":"us","top_or_hot":-1,"title":"BRIEF-Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted To Tividenofusp Alfa For The Treatment Of Hunter Syndrome (MPS II)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Denali <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces U.S. FDA Breakthrough Therapy Designation Granted To Tividenofusp Alfa For The Treatment Of Hunter Syndrome (MPS II)</title></head><body><p><span>Jan 8 (Reuters)</span><span> - </span>Denali Therapeutics Inc <span>DNLI.O</span>:</p><ul><li><p>DENALI THERAPEUTICS ANNOUNCES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION GRANTED TO TIVIDENOFUSP ALFA FOR THE TREATMENT OF HUNTER SYNDROME (MPS II)</p></li><li><p>DENALI THERAPEUTICS INC - EXPECTS TO SUBMIT BLA FOR TIVIDENOFUSP ALFA IN EARLY 2025</p></li></ul><p>Source text: <span>nGNX1hSTYb</span></p><p>Further company coverage: <span>DNLI.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>BRIEF-Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted To Tividenofusp Alfa For The Treatment Of Hunter Syndrome (MPS II)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted To Tividenofusp Alfa For The Treatment Of Hunter Syndrome (MPS II)\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-08 21:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<title>BRIEF-Denali <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces U.S. FDA Breakthrough Therapy Designation Granted To Tividenofusp Alfa For The Treatment Of Hunter Syndrome (MPS II)</title><p><span>Jan 8 (Reuters)</span><span> - </span>Denali Therapeutics Inc <span>DNLI.O</span>:</p><ul><li><p>DENALI THERAPEUTICS ANNOUNCES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION GRANTED TO TIVIDENOFUSP ALFA FOR THE TREATMENT OF HUNTER SYNDROME (MPS II)</p></li><li><p>DENALI THERAPEUTICS INC - EXPECTS TO SUBMIT BLA FOR TIVIDENOFUSP ALFA IN EARLY 2025</p></li></ul><p>Source text: <span>nGNX1hSTYb</span></p><p>Further company coverage: <span>DNLI.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DNLI","symbol_name":"Denali Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA1K1QJY:1","article_id":"2501727284","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501727284","pubTimestamp":1736344403,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted To Tividenofusp Alfa For The Treatment Of Hunter Syndrome Jan 8  - Denali Therapeutics Inc DNLI.O:DENALI THERAPEUTICS ANNOUNCES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION GRANTED TO TIVIDENOFUSP ALFA FOR THE TREATMENT OF HUNTER SYNDROME DENALI THERAPEUTICS INC - EXPECTS TO SUBMIT BLA FOR TIVIDENOFUSP ALFA IN EARLY 2025Source text: nGNX1hSTYbFurther company coverage: DNLI.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DNLI":"Denali Therapeutics Inc.","BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4535":"淡马锡持仓"},"translate_title":"简介-Denali Therapeutics宣布美国FDA授予Tividenofusp Alfa治疗亨特综合征(MPS II)的突破性疗法认定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNLI":0.9},"content_text":"BRIEF-Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted To Tividenofusp Alfa For The Treatment Of Hunter Syndrome (MPS II)Jan 8 (Reuters) - Denali Therapeutics Inc DNLI.O:DENALI THERAPEUTICS ANNOUNCES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION GRANTED TO TIVIDENOFUSP ALFA FOR THE TREATMENT OF HUNTER SYNDROME (MPS II)DENALI THERAPEUTICS INC - EXPECTS TO SUBMIT BLA FOR TIVIDENOFUSP ALFA IN EARLY 2025Source text: nGNX1hSTYbFurther company coverage: DNLI.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1}}}